Validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis

Multiple Sclerosis Journal - Experimental Translational and Clinical, Год журнала: 2022, Номер 8(2)

Опубликована: Апрель 1, 2022

Disability assessment using the Expanded Status Scale (EDSS) is important to inform treatment decisions and monitor progression of multiple sclerosis. Yet, EDSS scores are documented infrequently in electronic medical records.To validate a machine learning model estimate for sclerosis patients clinical notes from neurologists.A was developed on specific encounter dates neurologist visits. The OM1 MS Registry data were used create training cohort 2632 encounters separate validation 857 encounters, all with clinician-recorded scores. Model performance assessed area under receiver-operating-characteristic curve (AUC), positive predictive value (PPV), negative (NPV), calculated binarized version outcome. Spearman R Pearson values calculated. then applied without Registry.The had PPV 0.85, NPV AUC 0.91. 0.75 0.74 when evaluating continuous estimated Application eligible resulted generation eEDSS an additional 190,282 13,249 patients.EDSS can be very good notes, thus increasing utility real-world sources research purposes.

Язык: Английский

---

Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab

Multiple Sclerosis and Related Disorders, Год журнала: 2019, Номер 33, С. 82 - 87

Опубликована: Май 28, 2019

Язык: Английский

---

Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis

Multiple Sclerosis Journal, Год журнала: 2022, Номер 28(14), С. 2263 - 2273

Опубликована: Сен. 21, 2022

Background: Overall Disability Response Score (ODRS) is a composite endpoint including Expanded Status Scale, Timed 25-foot Walk, and 9-Hole Peg Test, designed to quantify both disability improvement worsening in multiple sclerosis (MS). Objective: To assess the sensitivity clinical meaningfulness of ODRS using natalizumab Phase 3 data sets (AFFIRM relapsing-remitting MS ASCEND secondary progressive MS). Methods: Differences over 96 weeks, at Week 96, slope change per year between placebo groups were analyzed. Correlation changes patient-reported outcomes was also Results: The difference (95% confidence interval (CI)) weeks 0.34 (0.21–0.46) AFFIRM ( p < 0.001), 0.18 (0.03–0.34) = 0.021). Significant differences treatment arms observed studies. There significant linear correlation from baseline physical mental components 36-item Short Form Survey (SF-36) Conclusion: This analysis supports as sensitive potentially clinically meaningful outcome measure MS.

Язык: Английский

---

Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for multiple sclerosis

Multiple Sclerosis Journal, Год журнала: 2024, Номер 30(9), С. 1185 - 1192

Опубликована: Авг. 1, 2024

Background: The lack of standardized disability progression evaluation in multiple sclerosis (MS) hinders reproducibility clinical study results, due to heterogeneous and poorly reported criteria. Objective: To demonstrate the impact using different parameters when evaluating MS progression, introduce an automated tool for reproducible outcome computation. Methods: Re-analyzing BRAVO trial data (NCT00605215), we examined fluctuations computed treatment effect on confirmed (CDP) independent relapse activity (PIRA) varying parameters. These analyses were conducted msprog package R, which developed as a CDP assessment from longitudinal data, given set criteria that can be specified by user. Results: hazard ratio (HR) 0.69 (95% confidence interval (CI): 0.46–1.02) CDP. Using parameter configurations, resulting varied considerably, with HRs ranging 0.59 CI: 0.41–0.86) 0.72 0.48–1.07). PIRA HR = 0.62 0.41–0.93) 0.65 0.40–1.04). Conclusions: adoption open-access validated research community, clear specification output, could greatly reduce heterogeneity estimation promote repeatability results.

Язык: Английский

---

Interleukin-1 receptor antagonist: An exploratory plasma biomarker that correlates with disability and provides pathophysiological insights in relapsing-remitting multiple sclerosis

Multiple Sclerosis and Related Disorders, Год журнала: 2021, Номер 52, С. 103006 - 103006

Опубликована: Май 7, 2021

Язык: Английский

---